



Larka

Press release

Merger & Acquisition

11th of May, 2021

Larka provided Clean Biologics & Archimed with a Commercial Due-Diligence on their acquisition of Biodextris.



ArchiMed

biode**tr**is

clean
biologics



How Did Larka Support this M&A Process ?

In order to advise Archimed and Clean Biologics on Biodextris' growth potential and value-creating opportunities, Larka's M&A team has performed a comprehensive Commercial Due-Diligence.

As a **leading CDD advisor to Private Equity firms** within the BioPharma industry, Larka has leveraged its advanced analytics and extensive proprietary benchmarks to assess synergy value, growth potential and identify value-creating opportunities.

Commercial Due-Diligence

Commercial Due-Diligence within the BioPharma space is dramatically more complex than within other universe.

With close to **30 years** of experience and an unrivalled network of senior-level experts, our Biotech & Pharma industry knowledge is matchless.

We provide our Private Equity clients with **unparalleled insights** on market dynamics, customers environment and competitive landscape, target's business plan, risk and opportunities.

Contact

Pierre-Anthony Brioir, Director
+33 650 630 286
pabrioir@larka.com

Adrien Chalmont, Manager
+33 621 006 115
achalmont@larka.com

Larka is pleased to announce that it performed the **Commercial Due-Diligence** for **Clean Biologics group – backed by Archimed – on their acquisition of Biodextris.**

As a result of the M&A process, Clean Biologics, a group providing services for the BioPharma industry, has acquired Biodextris, a Biologics Contract Development and Manufacturing Organization - *CDMO* - based in Laval – *Montreal* –, Quebec. Biodextris provides analytical and process development, early-clinical phase manufacturing and quality control testing services for clients in the vaccine and biologics industries.

This acquisition enables Clean Biologics to expand its activities by including Biodextris' complementary services, but also provides an opportunity to establish its presence on the North American market, with the objective to expand its activities in this region.



Joe Zimmermann, president and CEO, Biodextris, highlighted that this acquisition will “position Biodextris for near-term expansion”. He also added: “we are excited to join forces with the Clean Biologics group and in the near future we look forward to introducing our shared client base to the advantages of this alliance.”

What's Next for Biodextris?

As a new entity within the Clean Biologics group, which includes Clean Cells - *previously acquired by Archimed during an M&A process also supported by Larka in 2018* – Biodextris will continue to expand its service portfolio, which currently includes analytical and process development, early-phase clinical manufacturing and quality control testing services for clients in the vaccine and biologics industries.



Joseph Jammal, president and CEO, Clean Biologics, confirmed that having Biodextris joining the group will “allow to provide broader services” to their customers, adding that “the cultures of the three companies in the group - *Clean Cells, Naobios and now Biodextris* - are very similar in terms of customer focus and personalization, making this acquisition a natural fit for the very promising expansion projects to come.”

About Clean Biologics

The Clean Biologics group provides services to the biopharmaceutical industry. These include quality control and manufacturing of biological starting materials, such as cell banks and virus seed stocks, and clinical batches of biological drugs through its two subsidiaries: Clean Cells and Naobios – *both of which offer complementary activities*. The group specializes in biological and viral safety of biopharmaceutical products, such as recombinant proteins, therapeutic antibodies, viral vaccines, phage therapy, and cell and gene therapy products.

For more information, please visit www.clean-biologics.com

About Biodextris

A Contract Development and Manufacturing Organization – *CDMO* – created in 2015 and based in Laval – *Montreal* – Canada, Biodextris provides analytical and process development, early-phase clinical manufacturing and quality control testing services for clients in the vaccine and biologics industries.

The Biodextris team has decades of expertise working in mid- and large-sized vaccine companies. It develops, manufactures and tests a wide range of biologic products for vaccine, pharmaceutical and other applications. It has worked on numerous products at all phases of clinical development for programs conducted in the US, Canada and Europe.

For more information, please visit www.biodextris.com

About Larka

Larka is a management consulting firm, exclusively dedicated to the Biotech and Pharma industry. We assist small Biotech or large Pharma companies, Contract Services Providers or Equipment Suppliers, Venture Capital or Private Equity firms, in their development or in managing complex situations. Active in Technical, Organizational, Commercial and Strategic operations, Larka has developed a unique combination of expertise which covers CMC & Outsourcing activities, Operational & Commercial excellence, Marketing & Sales, Corporate Strategy and M&A.

For more information, please visit www.larka.com